Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Rabenau, Holger F ^a   Rapp, Ingrid ^b   Steinmann, Jochen ^c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Labor Dr Merk and Kollegen   (Germany)

^c MikroLab GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 PROPANOL; ALCOHOL; ALDEHYDE; BIOCIDE; DISINFECTANT AGENT; GLUTARALDEHYDE; PERACETIC ACID;

ACCURACY; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; FETAL CALF SERUM; INOCULATION; MODIFIED VACCINIA ANKARA VIRUS; NONHUMAN; PRACTICE GUIDELINE; QUANTITATIVE STUDY; SPECIES DIFFERENCE; VACCINIA VIRUS; VIRUS INACTIVATION; VIRUS LOAD; VIRUS STRAIN; ANIMAL; CELL LINE; CERCOPITHECUS; COMPARATIVE STUDY; DRUG EFFECT; GERMANY; HAMSTER; HUMAN; METHODOLOGY; MICROBIAL VIABILITY; PATHOGENICITY; VIROLOGY;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; DISINFECTANTS; GERMANY; HUMANS; MICROBIAL VIABILITY; VACCINIA VIRUS; VIROLOGY;

EID: 77953695119     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-185     Document Type: Article

References (29)

1. CDC Supplement: collected recommendations of the Public Health Service Advisory Committee on Immunization Practices. MMWR 1972, 2:1. CDC.
2. Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. N Engl J Med 1980, 303(22):1263-73.
3. CDC Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR 2003, 52(RR-7). CDC.
4. Mayr A, Stickl H, Müller HK, Danner K, Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zbl Bakt Hyg I Abt Orig B 1978, 167:375-390.
5. Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, van Schalkwijk P, van der Kwast T, Wyatt LS, Moss B, Osterhaus AD. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001, 19(27):3700-3709. 10.1016/S0264-410X(01)00075-5, 11395204.
6. EN 14476 Chemical disinfectants and antiseptics. Virucidal quantitative suspension test for chemical disinfectants and antiseptics used in human medicine. Test method and requirements (phase 2, step 1). 2007, EN 14476.
7. Blümel J, Glebe D, Neumann-Haefelin D, Rabenau HF, Rapp I, von Rheinbaben F, Ruf B, Sauerbrei A, Schwebke I, Steinmann J, Willkommen H, Wolff MH, Wutzler P. Guideline of "Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten e.V." (DVV; German Association for the Control of Virus Diseases) and Robert Koch-Institute (RKI; German Federal Health Authority) for testing the virucidal efficacy of chemical disinfectants in the human medical area. Hyg Med 2009, 34(7/8):293-299.
8. Anonymous Prüfung und Deklaration der Wirksamkeit von Desinfektionsmitteln gegen Viren. Stellungnahme des Arbeitskreises Viruzidie beim Robert Koch-Institut (RKI) sowie des Fachausschusses Virusdesinfektion der Deutschen Gesellschaft zur Bekämpfung der Viruskrankheiten (DVV) und der Desinfektionsmittelkommission der Deutschen Gesellschaft für Hygiene und Mikrobiologie (DGHM). Bundesgesundhbl 2004, 47(1):62-66. 10.1007/s00103-003-0754-7, Anonymous.
9. Anonymous Richtlinien zur Prüfung chemischer Desinfektionsmittel für die Veterinärmedizin. Deutsche Veterinärmedizinische Gesellschaft e. V., Gießen 2000, Anonymous.
10. Auckland C, Cowlishaw A, Morgan D, Miller E. Reactions to small pox vaccine in naïve and previously-vaccinated individuals. Vaccine 2005, 23:4185-4187. 10.1016/j.vaccine.2004.10.052, 15916840.
11. Eckart RE, Shry EA, Jones SO, Atwood JE, Grabenstein JD. Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age. Am J Cardiol 2005, 95(10):1252-1255. 10.1016/j.amjcard.2005.01.061, 15878006.
12. Sejvar JJ, Labutta RK, Chapman LE, Grabenstein JD, Iskander J, Lane JM. Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA 2005, 294(21):2744-2750. 10.1001/jama.294.21.2744, 16333010.
13. CDC Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR 2006, 55(RR-1). CDC.
14. CDC Laboratory-acquired vaccinia exposures and infections---United States, 2005--2007. MMWR 2008, 57:401-404. CDC.
15. Lewis FM, Chernak E, Goldman E, Li Y, Karem K, Damon IK, Henkel R, Newbern EC, Ross P, Johnson CC. Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis 2006, 12:134-137.
16. Mempel M, Isa G, Klugbauer N, Meyer H, Wildi G, Ring J, Hofmann F, Hofmann H. Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct. J Invest Dermatol 2003, 120(3):356-358. 10.1046/j.1523-1747.2003.12074.x, 12603846.
17. Openshaw PJM, Alwan WH, Cherrie AH, Record FM. Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet 1991, 338:459. 1678128, 10.1016/0140-6736(91)91093-A.
18. Rupprecht CE, Blass L, Smith K, Orciari LA, Niezgoda M, Whitfield SG, Gibbons RV, Guerra M, Hanlon CA. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med 2001, 345:582-586. 10.1056/NEJMoa010560, 11529212.
19. Wlodaver CG, Palumbo GJ, Waner JL. Laboratory-acquired vaccinia infection. J Clin Virol 2004, 29:167-170. 10.1016/S1386-6532(03)00118-5, 14962785.
20. CDC Laboratory-Acquired Vaccinia Virus Infection - Virginia, 2008. MMWR 2009, 58(29):797-800. CDC.
21. Hartnack S, Essbauer S, Truyen U. Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants. Zoonoses Public Health 2008, 55(2):99-105.
22. Spearman C. The method of "right and wrong cases" ("constant stimuli") without Gauss's formulae. British Journal of Psychology 1908, 2:227-242.
23. Kaerber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharmako 1931, 162:480-483.
24. Slifka MK. The future of smallpox vaccination: is MVA the key?. Med Immunol 2005, 4(1):2. 10.1186/1476-9433-4-2, 554756, 15740619.
25. Kemper A, Davis M, Freed G. Expected adverse events in a mass smallpox vaccination campaign. Effect Clin Pract 2002, 5:84-90.
26. Just I, Finke H. A contribution to the stability of the MVA-vaccine. ZBL Bakt Hyg I Abt Orig 1979, A245:276-282.
27. Newman FK, Frey SE, Blevins TP, Yan L, Belshe RB. Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax. J Infect Dis 2003, 187(8):1318-1322.
28. Kline RL, Regnery RL, Armstrong GL, Damon IK. Stability of diluted smallpox vaccine under simulated clinical conditions. Vaccine 2005, 23(41):4944-4946. 10.1016/j.vaccine.2005.05.016, 16005123.
29. Lee KN, Hutson CL, Kline R, Curns AT, Dougherty C, Allen C, Damon I, Regnery R. Smallpox vaccine stability after maintenance at temperatures not recommended for shipping. Vaccine 2006, 24(7):884-886. 10.1016/j.vaccine.2005.08.079, 16183175.